Australia markets closed

Prestige BioPharma Limited (950210.KS)

KSE - KSE Delayed price. Currency in KRW
Add to watchlist
8,730.00+340.00 (+4.05%)
At close: 03:30PM KST

Prestige BioPharma Limited

21 Biopolis Road
No. 04-24/28 Nucleos South Building
Singapore 138567
Singapore
65 6924 6535
https://www.prestigebiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Ms. So-Yeon ParkChairman & CEON/AN/A1963
Mr. Lai Wat TayCFO & DirectorN/AN/A1956
Mr. Michael Jinwoo KimCOO & DirectorN/AN/A1964
Ms. Chung Shii HiiChief Technology OfficerN/AN/A1979
Ms. Kay K.H. LeeClinical Development ManagerN/AN/A1970
Mr. Ghislain M.C BonamyGeneral Manager of LicensingN/AN/A1979
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.

Corporate governance

Prestige BioPharma Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.